Revolade (eltrombopag) - Risk Of Severe Hepatotoxicity

REVOLADE Recall Summary Revolade (eltrombopag), a medication used to treat low platelet counts, is being recalled across Canada due to a risk of severe liver damage. The recall affects all lots of this drug that have been distributed throughout Canada. Patients currently taking this medication should contact their healthcare provider for guidance.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-08-25

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/7ca502bf-c7ef-4050-94f3-e8f9a2cbe2ab